Human Parvovirus B19 Infection in Persons with Haemophilia

Thromb Haemost 1998; 80(02): 351
DOI: 10.1055/s-0037-1615208

Letters to the Editor

Schattauer GmbH

C. Prowse

¹SNBTS National Science Laboratory, Edinburgh

,

B. Dow

²SNBTS Microbiology Reference Unit

,

S. J. Pelly

³SNBTS Product Services Department

,

E. McIntosh

³SNBTS Product Services Department

,

S. Reading

³SNBTS Product Services Department

,

G. D. O. Lowe

⁴Department of Medicine, Royal Infirmary, Glasgow

,

B. Gibson

⁵Royal Hospital for Sick Children, Glasgow

,

P. Cachia

⁶Ninewells Hospital, Dundee

,

A. Thomas

⁷Royal Hospital for Sick Children, Edinburgh and Royal Infirmary, Edinburgh, UK

,

R. Dennis

⁸Royal Infirmary, Edinburgh, UK

,

C. A. Ludlam

⁸Royal Infirmary, Edinburgh, UK

References
1 Aygören-Pürsün E, Scharrer I. German Kogenate Study Group.. A multicentre pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant Factor VIII in the treatment of patients with haemophilia A.. Thromb Haemost 1998; 78: 1352-6.
2 Prowse CV. Parvovirus B19 and blood products.. Lancet 1994; 343: 1101.
3 Prowse CV, Ludlam CA, Yap PL. Human parvovirus B19 and blood products.. Vox Sang, 1998; 72: 1-10.
4 Prowse CV, Dow B, Pelly J. et al. Studies on B19 parvovirus in the normal and haemophilic. Scottish population in 1995.. Thromb Haemost 1998; Suppl: 455 (PS-1857).
5 Williams MD, Cohen BJ, Beddall AC, Pasi RJ, Mortimer P, Hill FGW. Transmission of human parvovirus B19 by coagulation factor concentrates.. Vox Sang 1990; 58: 177-81.